H0252
Hydroxyapatite
Type I, buffered aqueous suspension
Synonym(s):
Calcium phosphate hydroxide, Durapatite, Hydroxylapatite
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
3Ca3(PO4)2 · Ca(OH)2
CAS Number:
Molecular Weight:
502.31
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12161700
EC Number:
215-145-7
MDL number:
Form:
buffered aqueous suspension
type
Type I
Quality Level
form
buffered aqueous suspension
storage temp.
2-8°C
SMILES string
[Ca++].[Ca++].[Ca++].[Ca++].O[Ca+].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O
InChI
1S/5Ca.3H3O4P.H2O/c;;;;;3*1-5(2,3)4;/h;;;;;3*(H3,1,2,3,4);1H2/q5*+2;;;;/p-10
InChI key
XYJRXVWERLGGKC-UHFFFAOYSA-D
Application
Useful in the purification of proteins and nucleic acids
Packaging
Package size based on dry weight
Physical form
Suspension in 0.001 M phosphate buffer, pH 6.8; approx. 25% solids
Still not finding the right product?
Explore all of our products under Hydroxyapatite
Storage Class
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Sophie E P New et al.
Circulation research, 113(1), 72-77 (2013-04-26)
We previously showed that early calcification of atherosclerotic plaques associates with macrophage accumulation. Chronic renal disease and mineral imbalance accelerate calcification and the subsequent release of matrix vesicles (MVs), precursors of microcalcification. We tested the hypothesis that macrophage-derived MVs contribute
Bjarke Viberg et al.
Acta orthopaedica, 84(3), 254-259 (2013-04-19)
Elderly patients with displaced femoral neck fractures are commonly treated with a hemiarthroplasty (HA), but little is known about the long-term failure of this treatment. We compared reoperation rates for patients aged at least 75 years with displaced femoral neck
Ehud Segal et al.
PloS one, 4(4), e5233-e5233 (2009-04-22)
There is an immense clinical need for novel therapeutics for the treatment of angiogenesis-dependent calcified neoplasms such as osteosarcomas and bone metastases. We developed a new therapeutic strategy to target bone metastases and calcified neoplasms using combined polymer-bound angiogenesis inhibitors.
Global Trade Item Number
| SKU | GTIN |
|---|---|
| H0252-25G | 04061832862231 |
| H0252-65G | 04061832401638 |
| H0252-250G | 04061832401621 |